« eMerge Americas Techweek: Dominicana Tech announced | Main | Healthcare a hot topic at eMerge Americas Techweek »

eMerge Americas Techweek: And the later-stage company winner is ...

 

The already quite successful Modernizing Medicine took the big win in the later-stage company pitch competition on the final day of Emerge Americas Techweek on Tuesday.

Ten finalists delivered their five-minute pitches in front of a live audience and a four-judge panel, including former U.S. Senator George LeMieux, who now serves as Chairman of law firm Gunster Yoakley. At stake: $100,000 in cash and services.

Launched in 2010 and based in Boca Raton, Modernizing Medicine provides a cloud-based electronic medical records system for specialized medical areas, including the dermatology, ophthalmology, optometry, orthopedics and plastic and cosmetic surgery markets.  The company received $14 million in Series C funding last year, after receiving $7 million and $8 million dollars in previous rounds.

Upon receiving the trophy, Modernizing Medicine’s serial entrepreneurial founder, Daniel Cane, turned around and promised to donate the money to the local entrepreneurial community. The founder of Blackboard mentioned the possibility of helping university students. We'll follow up to find out who got the money.

Other finalists were: Azzly, CareCloud, Early Shares, eTect, Inzpiral, Kairos, LinguaSys, Neocis and Wedemand.

Judges: Mike Tomas of Bioheart; Senator George LeMieux, Gunster; Al Dosal, Dosal Capital, Jocelyn Cortez Young, Minerva Capital Group; Blake Menefee, Dell Center for Entrepreneurship; Carmen Perez, FPL Fibernet.
 
Update:  Modernizing Medicine announced the winnings would be donating to Florida Atlantic University’s Tech Runway, the C. Scott Ellington Technology Business Incubator at the Research Park at FAU, Venture Hive in downtown Miami and Florida Internationa lUniversity.

Karen Rundlett

Video by Karen Rundlett

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

The comments to this entry are closed.